Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

and expectations. These forward-looking statements include statements regarding the timing of enrollment and rate of MACE in the Light Study, the ability to gain agreement with FDA on the procedural details for a Contrave NDA resubmission in advance of the Light Study interim data, the timing of the subsequent resubmission of the NDA for Contrave, the timing of approval for Contrave, the submission of an application for marketing authorization in Europe and the negotiation of a partnership for the rest-of-world rights to Contrave and Empatic, the expected cash balance at the end of 2012, the expected cash usage for the year 2012, the development of Empatic and the communication with the FDA, the possibility that a cardiovascular outcomes trial will be needed for Empatic, and the commercial potential of Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct the Light Study and the progress and timing thereof; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study or Phase III trials for Empatic; the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave or Empatic; the potential for early termination of the collaboration agreement betwe
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Sequence, Inc., an industry leader ... biotech and medical device manufacturers is opening a third office ... Louis , as a result of demand by clients ... which opened this month, allows Sequence to better serve new ... St. Louis office provides Sequence a ...
(Date:8/19/2014)... August 19, 2014 According to ... (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast, 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:8/18/2014)... HERZLIYA-PITUACH, Israel , Aug. 19, 2014 /PRNewswire/ ... Premier, Stockholm : "IMNP"), a biotechnology company, ... to list its common stock on the NASDAQ Capital Market ... of the NASDAQ OMX Group. IMMUNE,s common stock is expected ... opening of trading on August 21, 2014 under the symbol ...
Breaking Medicine Technology:Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:8/19/2014)... LunaDress, a popular supplier of fashionable ... ladies, is now providing a discount of up to ... company’s cheap white prom outfits are available in different ... outfits. , There are over 400 cheap white ... the special offer is valid until August 29, 2014. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... 2014 The National Cannabis Industry ... Southwest CannaBusiness Symposium on Saturday, August 23, from ... in Las Vegas. , Featuring keynotes by U.S. Representative ... (D-Las Vegas), the event will also include in-depth discussions ... NCIA is doing federally to advance a legitimate and ...
(Date:8/19/2014)... Drews Dental Services is proud to announce the recent election ... Maine Dental Association (MDA). After serving on the Executive Board ... been sworn in to his new position. , Dr. Drews ... and being a part of the ADA House of Delegates ... 2015. He plans to advocate for the profession of dentistry ...
(Date:8/19/2014)... Tara Haelle HealthDay ... -- Kidney injury can be added to the list ... medications often prescribed to treat behavioral symptoms of dementia ... (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) are approved by ... disorder, schizophrenia and other serious mental disorders. They are ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:Dr. Drews Elected VP of Maine Dental Association 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... parents of Canada’s conjoined twins and to the public, who ... of several tests that the twins are growing normally. ... Tatiana Hogan came into the world with their heads joined. ... sleep patterns, vision, hearing and responses to touch. , ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... has titillated the curiosity of investigators, by defying the ... the diagnosis of the disease, is absent in this ... not recognize this new strain, making detection of gonorrhea ... question, playing truant in this odd strain of gonorrhea, ...
... in the war against polio, Chief Minster Sheila Dikshit Saturday ... will be immunized Sunday. ,Launching another round of ... of children at her official residence here. ,Delhi ... just one case in 2005. ,'The only threat ...
... presented today shows angioplasty and stenting can prevent amputation ... patients// with severe critical limb ischemia and gangrene (tissue ... knee remained open, with a ninety-one percent success rate, ... all patients who were consecutively enrolled over a six-year ...
... as well kick the butt. There will be no escape into ... be- released bill// of British Columbia hits the public. ... ban smoking in all indoor public spaces as well as in ... any building accessible by the public. , Says Health ...
Cached Medicine News:Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Multi-Year Data Shows PAD Treatment Prevents Amputation 2
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: